Referred to the House Committee on Energy and Commerce.
The bill directs HHS to study how often hospital emergency departments test for fentanyl when treating overdoses, the costs, benefits, risks, and effects on patient experience and privacy. Within six months after the study, HHS must issue guidance on whether EDs should routinely test for fentanyl, how clinicians can know which substances tests cover, and how such testing may affect future overdose risk and health outcomes.
Whether testing should be routine versus voluntary
Relative to its intended legislative type, this bill is a well-focused study-and-guidance directive.
The bill directs HHS to study how often hospital emergency departments test for fentanyl when treating overdoses, the costs, benefits, risks, and effects on patient experience and privacy.
Within six months after the study, HHS must issue guidance on whether EDs should routinely test for fentanyl, how clinicians can know which substances tests cover, and how such testing may affect future overdose risk and health outcomes.
Content is narrow and technocratic, favoring passage; nonetheless many benign bills stall in committee or face floor scheduling and procedural barriers.
Relative to its intended legislative type, this bill is a well-focused study-and-guidance directive. It specifies the responsible agency, concrete study elements, a statutory definition, and deadlines for both study completion and issuance of guidance.
Whether testing should be routine versus voluntary
These are examples from the analysis, not a ranked list of the most-affected groups.
Whether testing should be routine versus voluntary
Likely supportive because the bill promotes evidence-based responses to the overdose crisis and could improve clinical care and harm reduction.
Would stress safeguards for patient privacy, limits on law-enforcement access, and linkage to treatment and social supports.
Would want the guidance used to expand harm-reduction measures, not to penalize patients.
Generally favorable toward a federally-led study and subsequent guidance as measured, evidence-based policymaking.
Willing to support guidance but cautious about unfunded mandates, implementation costs, and unintended effects on care-seeking.
Wants clarity on costs, reimbursement, and protections before endorsing routine testing.
Likely supports a study but is skeptical of federal guidance pushing routine testing or expanding federal influence.
Concerned about costs, hospital autonomy, patient privacy, and potential use of test results by law enforcement.
Prefers voluntary, state-led approaches and protections against bureaucratic mandates.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Content is narrow and technocratic, favoring passage; nonetheless many benign bills stall in committee or face floor scheduling and procedural barriers.
The bill has not accumulated any surfaced votes yet.
Whether testing should be routine versus voluntary
Content is narrow and technocratic, favoring passage; nonetheless many benign bills stall in committee or face floor scheduling and procedu…
Relative to its intended legislative type, this bill is a well-focused study-and-guidance directive. It specifies the responsible agency, concrete study elements, a statutory definition, and deadlines for both study com…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.